Critical lessons from the ENHANCE trial.
Greenland
Philip
P
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA.
Lloyd-Jones
Donald
D
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000517:prevention & control*; D001384:Azetidines / Q000627:therapeutic use; D002339:Carotid Arteries / Q000000981:diagnostic imaging*; D016265:Conflict of Interest; D003627:Data Interpretation, Statistical; D017277:Drug Approval; D004345:Drug Industry; D000069438:Ezetimibe; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008402:Mass Media; D016032:Randomized Controlled Trials as Topic; D019821:Simvastatin / Q000627:therapeutic use; D014463:Ultrasonography
D000924:Anticholesteremic Agents; D001384:Azetidines; D019821:Simvastatin; D000069438:Ezetimibe